Skip to main content
OpenTrials
Completed

NCT Number: NCT02924129

Safety and Efficacy Study of the Evoke™ SCS System With Feedback vs. Conventional Stimulation

The purpose of this study is to evaluate the safety and efficacy of the Saluda Medical Evoke SCS System with feedback control to treat chronic pain of the trunk and/or limbs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hope Research Institute, Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is male or female between the ages of 18 and 80 years.
  • Have been diagnosed with chronic, intractable pain of the trunk and/or limbs, which has been refractory to conservative therapy for a minimum of 6 months.
  • Be an appropriate candidate for an SCS trial and the surgical procedures required in this study based on the clinical judgment of the Investigator.
  • Be willing and capable of giving informed consent and able to comply with study-related requirements, procedures, and visits.

Exclusion criteria

  • Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator.
  • Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and/or ability to evaluate treatment outcomes.
  • Have an existing drug pump and/or SCS system or another active implantable device such as a pacemaker, deep brain stimulator (DBS), or sacral nerve stimulator (SNS).
  • Have prior experience with SCS.
  • Have an active systemic infection or local infection in the area of the surgical site.
  • Be pregnant or nursing (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile, or be at least 2 years post-menopausal).
  • Be concomitantly participating in another clinical study.

Treatment and study plan

Evoke Spinal Cord Stimulator (SCS) System

Device

Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).

Primary outcomes

  1. Number of Participants With Composite Endpoint Success

    Time frame: 3 months

    The primary endpoint is a composite endpoint. A success is defined as a reduction in overall trunk and limb VAS pain score greater than or equal to 50 percent and no increase in baseline pain medication. VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain.

Secondary outcomes

  1. Percent Change From Baseline in Leg Pain VAS Score

    Time frame: 3 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain.

  2. Percent Change From Baseline in Back Pain VAS Score

    Time frame: 3 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain.

  3. Proportion of Subjects With Greater Than or Equal to 80% Reduction From Baseline in Overall Trunk and Limb Pain VAS Score

    Time frame: 3 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain.

  4. Proportion of Subjects With Greater Than or Equal to 50% Reduction From Baseline in Back Pain VAS Score

    Time frame: 3 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain

  5. Number of Participants With Composite Endpoint Success

    Time frame: 12 months

    The primary endpoint is a composite endpoint. A success is defined as a reduction in overall trunk and limb VAS pain score greater than or equal to 50 percent and no increase in baseline pain medication. VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain.

  6. Percent Change From Baseline in Leg Pain VAS Score

    Time frame: 12 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain

  7. Percent Change From Baseline in Back Pain VAS Score

    Time frame: 12 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain

  8. Proportion of Subjects With Greater Than or Equal to 80% Reduction From Baseline in Overall Trunk and Limb Pain VAS Score

    Time frame: 12 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain

  9. Proportion of Subjects With Greater Than or Equal to 50% Reduction From Baseline in Back Pain VAS Score

    Time frame: 12 months

    VAS = Visual Analog Scale, from 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain

Sponsors and collaborators

Lead sponsor

Saluda Medical Americas, Inc.

Industry

Registry information

Official study title

A Prospective, Multicenter, Randomized Double-blind Study Examining the Safety and Efficacy of Using the Evoke™ Spinal Cord Stimulator (SCS) System With Feedback to Treat Patients With Chronic Pain of the Trunk and/or Limbs.

Acronym: EVOKE

Important dates

Study start
2017
Primary completion
2018
Study completion
2022
First posted
Oct 5, 2016
Registry last updated
Jan 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.